Chemical structures and descriptions

Cystatin C

1G96
www.uniprot.org

What is measured?

Native cystatin C (CnCn), 3Pro-OH cystatin C (CnCo), cystatin C-desS (CnCds), 3Pro-OH cystatin C-desS (CnCods) and cystatin C-desSSP (CnCdssp). CnCt is the total concentration of detected cystatin C proteoforms.
Method(s): MALDI-TOF MS (1).

What is cystatin C?

Cystatin C is a non-glycosylated cysteine protease inhibitor with a molecular weight of 13 kDa. It is produced at a constant rate by nucleated cell and freely filtered by the renal glomerulus, and serum cystatin C is an established marker of renal function. Cystatin C is a more specific marker of glomerular filtration rate than creatinine, because levels are independent of age, sex, muscle mass and diet (2). In addition, high cystatin C is associated with elevated risk of death from myocardial infarction, stroke, and metabolic syndrome. Higher levels of cystatin C and the presence of certain isoforms have also been related to neurological and cerebral disorders such as cerebral amyloid angiopathy, amyotrophic lateral sclerosis, multiple sclerosis, and Alzheimer’s disease. Cystatin isoforms can be detected both in serum and cerebrospinal fluid and more than a dozen have been reported so far.

Indication(s)

Assessment of renal function.

Specimen, collection and processing

Matrix: EDTA plasma and serum. Cystatin C is stable for 3 month at -20 °C.
Volume: Minimum volume is 30 µL, but 100 µL is optimal and allows reanalysis.
Preparation: The blood sample must be centrifuged and the plasma/serum fraction put on ice, and frozen.

Stability

Cystatin C is stable for 3 month at -20 °C. Long-term storage requires -80 °C. 

Transportation

Frozen, on dry ice. (for general instruction on transportation, click here)

Reported values, interpretation

Reported values: 0-7 µg/ml.
Intraclass correlation coefficient (ICC): 0.7.

Literature

1. Gao, J., Meyer, K., Borucki, K., and Ueland, P.M. (2018). Multiplex immuno-MALDI-TOF MS for targeted quantification of protein biomarkers and their proteoforms related to inflammation and renal dysfunction. Anal Chem 90, 3366-373.
2. Ferguson, T.W., Komenda, P., and Tangri, N. (2015). Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens 24, 295-300.

Scroll to Top

Statistical power is the probability that a statistical test will correctly reject a false null hypothesis (H0​) when a specific alternative hypothesis (H1​) is true. H0​ is the null hypothesis, which states there is no effect or no difference. H1​ is the alternative hypothesis, which states there is a real effect or difference. Alpha (α) is the probability of a Type I error (a false positive), which is the risk of incorrectly rejecting the H0​ when it is actually true. You set this value before the experiment, commonly at 0.05. Beta (β) is the probability of a Type II error (a false negative), which is the risk of failing to reject the H0​ when it is actually false.

Power is calculated as 1−β. Increasing power means you are decreasing the probability of making a Type II error.

Several factors can be adjusted to increase the power of a statistical test:

  • Effect Size: This is the magnitude of the difference you are trying to detect. A larger effect size is easier to detect, thus increasing power. 

  • Sample Size: The number of observations in a study. A larger sample size provides more information about the population, reducing the margin of error and increasing the power to detect a true effect.

  • Variation: Refers to the spread or standard deviation of the data within the population. Less variation makes it easier to distinguish a real effect from random noise, thereby increasing power.

  • Alpha (): Increasing the alpha level (e.g., from 0.05 to 0.10) also increases power, but at the cost of a higher risk of a Type I error. This trade-off is often undesirable.

562 entries « 28 of 29 »
541.

Refsum, H; Yajnik, C S; Gadkari, M; Schneede, J; Vollset, S E; Orning, L; Guttormsen, A B; Joglekar, A; Sayyad, M G; Ulvik, A; Ueland, P M

Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians Journal Article

In: Am J Clin Nutr, vol. 74, no. 2, pp. 233–241, 2001, ISSN: 0002-9165.

Abstract | Links | BibTeX

542.

Vollset, S E; Refsum, H; Tverdal, A; Nygård, O; Nordrehaug, J E; Tell, G S; Ueland, P M

Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study Journal Article

In: Am J Clin Nutr, vol. 74, no. 1, pp. 130–136, 2001, ISSN: 0002-9165.

Abstract | Links | BibTeX

543.

Ulvik, A; Evensen, E T; Lien, E A; Hoff, G; Vollset, S E; Majak, B M; Ueland, P M

Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum Journal Article

In: Am J Med Genet, vol. 101, no. 3, pp. 246–254, 2001, ISSN: 0148-7299.

Abstract | Links | BibTeX

544.

Chambers, J C; Ueland, P M; Wright, M; Doré, C J; Refsum, H; Kooner, J S

Investigation of relationship between reduced, oxidized, and protein-bound homocysteine and vascular endothelial function in healthy human subjects Journal Article

In: Circ Res, vol. 89, no. 2, pp. 187–192, 2001, ISSN: 1524-4571.

Abstract | Links | BibTeX

545.

Guttormsen, A B; Ueland, P M; Kruger, W D; Kim, C E; Ose, L; Følling, I; Refsum, H

Disposition of homocysteine in subjects heterozygous for homocystinuria due to cystathionine beta-synthase deficiency: relationship between genotype and phenotype Journal Article

In: Am J Med Genet, vol. 100, no. 3, pp. 204–213, 2001, ISSN: 0148-7299.

Abstract | Links | BibTeX

546.

El-Khairy, L; Ueland, P M; Refsum, H; Graham, I M; and, S E Vollset

Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project Journal Article

In: Circulation, vol. 103, no. 21, pp. 2544–2549, 2001, ISSN: 1524-4539.

Abstract | Links | BibTeX

547.

Ueland, P M; Hustad, S; Schneede, J; Refsum, H; Vollset, S E

Biological and clinical implications of the MTHFR C677T polymorphism Journal Article

In: Trends Pharmacol Sci, vol. 22, no. 4, pp. 195–201, 2001, ISSN: 0165-6147.

Abstract | Links | BibTeX

548.

Nurk, E; Tell, G S; Nygård, O; Refsum, H; Ueland, P M; Vollset, S E

Plasma total homocysteine is influenced by prandial status in humans: the Hordaland Hhomocysteine Sstudy Journal Article

In: J Nutr, vol. 131, no. 4, pp. 1214–1216, 2001, ISSN: 0022-3166.

Abstract | Links | BibTeX

549.

Vollset, S E; Refsum, H; Ueland, P M

Population determinants of homocysteine Miscellaneous

2001, ISSN: 0002-9165.

Links | BibTeX

550.

Dekou, V; Whincup, P; Papacosta, O; Ebrahim, S; Lennon, L; Ueland, P M; Refsum, H; Humphries, S E; Gudnason, V

The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study Journal Article

In: Atherosclerosis, vol. 154, no. 3, pp. 659–666, 2001, ISSN: 0021-9150.

Abstract | Links | BibTeX

551.

Ueland, P M; Nygård, O; Vollset, S E; Refsum, H

The Hordaland Homocysteine Studies Journal Article

In: Lipids, vol. 36 Suppl, pp. S33–S39, 2001, ISSN: 0024-4201.

Abstract | Links | BibTeX

552.

Bolann, B J; Solli, J D; Schneede, J; Grøttum, K A; Loraas, A; Stokkeland, M; Stallemo, A; Schjøth, A; Bie, R B; Refsum, H; Ueland, P M

Evaluation of indicators of cobalamin deficiency defined as cobalamin-induced reduction in increased serum methylmalonic acid Journal Article

In: Clin Chem, vol. 46, no. 11, pp. 1744–1750, 2000, ISSN: 0009-9147.

Abstract | BibTeX

553.

Chambers, J C; Ueland, P M; Obeid, O A; Wrigley, J; Refsum, H; Kooner, J S

Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine Journal Article

In: Circulation, vol. 102, no. 20, pp. 2479–2483, 2000, ISSN: 1524-4539.

Abstract | Links | BibTeX

554.

Louwman, M W; van Dusseldorp, M; van de Vijver, F J; Thomas, C M; Schneede, J; Ueland, P M; Refsum, H; van Staveren, W A

Signs of impaired cognitive function in adolescents with marginal cobalamin status Journal Article

In: Am J Clin Nutr, vol. 72, no. 3, pp. 762–769, 2000, ISSN: 0002-9165.

Abstract | Links | BibTeX

555.

Hustad, S; Ueland, P M; Vollset, S E; Zhang, Y; Bjørke-Monsen, A L; Schneede, J

Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism Journal Article

In: Clin Chem, vol. 46, no. 8 Pt 1, pp. 1065–1071, 2000, ISSN: 0009-9147.

Abstract | BibTeX

556.

Ueland, P M; Refsum, H; Beresford, S A; Vollset, S E

The controversy over homocysteine and cardiovascular risk Journal Article

In: Am J Clin Nutr, vol. 72, no. 2, pp. 324–332, 2000, ISSN: 0002-9165.

Abstract | Links | BibTeX

557.

Nexo, E; Engbaek, F; Ueland, P M; Westby, C; O'Gorman, P; Johnston, C; Kase, B F; Guttormsen, A B; Alfheim, I; McPartlin, J; Smith, D; Møller, J; Rasmussen, K; Clarke, R; Scott, J M; Refsum, H

Evaluation of novel assays in clinical chemistry: quantification of plasma total homocysteine Journal Article

In: Clin Chem, vol. 46, no. 8 Pt 1, pp. 1150–1156, 2000, ISSN: 0009-9147.

Abstract | BibTeX

558.

Mudd, S H; Finkelstein, J D; Refsum, H; Ueland, P M; Malinow, M R; Lentz, S R; Jacobsen, D W; Brattström, L; Wilcken, B; Wilcken, D E; Blom, H J; Stabler, S P; Allen, R H; Selhub, J; Rosenberg, I H

Homocysteine and its disulfide derivatives: a suggested consensus terminology Journal Article

In: Arterioscler Thromb Vasc Biol, vol. 20, no. 7, pp. 1704–1706, 2000, ISSN: 1079-5642.

Links | BibTeX

559.

Vollset, S E; Refsum, H; Irgens, L M; Emblem, B M; Tverdal, A; Gjessing, H K; Monsen, A L; Ueland, P M

Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study Journal Article

In: Am J Clin Nutr, vol. 71, no. 4, pp. 962–968, 2000, ISSN: 0002-9165.

Abstract | Links | BibTeX

560.

Lien, E A; Nedrebø, B G; Varhaug, J E; Nygård, O; Aakvaag, A; Ueland, P M

Plasma total homocysteine levels during short-term iatrogenic hypothyroidism Journal Article

In: J Clin Endocrinol Metab, vol. 85, no. 3, pp. 1049–1053, 2000, ISSN: 0021-972X.

Abstract | Links | BibTeX

562 entries « 28 of 29 »

Olink Proteomics

Please fill out the fields below (*required).
We will respond to you ASAP.
Thank you!

Customized analyses

Please fill out the fields below (*required).
We will reply to you soon for a detailed project discussion.
Thank you for reaching out to Bevital!

Mix-and-Match

Please fill out the fields below (*required).
We will respond to you as soon as possible.

Ready-to-Run

Please fill out the fields below (*required).
We will respond ASAP.
Thank you!

Thanks for joining!

Get updates about new method developments, publications and comming events.